Robert Nelsen is a co-founder and Managing Director of ARCH Venture Partners. He played a significant role in the early sourcing, financing and development of more than thirty companies, including twenty which reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); GRAIL, Sana, Vir Biotechnology, Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics; NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Arivale, Fate Therapeutics (FATE); NextCODE Health; and Everyday Learning Corporation.